Special Issue

Molecular Research in Chronic Dermatoses, 2nd Edition

Message from the Guest Editors

Chronic inflammatory dermatoses are a group of skin disorders characterized by recurrent and debilitating course and destructive influence on patients' quality of life. In recent years outstanding progress in understanding the molecular mechanisms behind the pathogenesis of inflammatory dermatoses has been made. The studies led to the development of new therapies, including biologics (chimeric, humanized, and human monoclonal antibodies) and their biosimilars, as well as systemic and topical small molecules (e.g. JAK inhibitors), which have revolutionized the management of patients suffering from chronic inflammatory dermatoses. Nevertheless, there are still many unmet needs of currently available therapies. Therefore, following with the first edition, our aim is to publish state of art articles about the molecular mechanisms in. among others, hidradenitis suppurativa, psoriasis, atopic dermatitis, alopecia areata, vitiligo, and chronic spontaneous urticaria. This Special Issue will accept review articles, original research, and updated information on the pathophysiology and molecular pathways.

Guest Editors

Dr. Antonio Martorell-Calatayud

Department of Dermatology, Hospital Manises, 46940 Valencia, Spain

Dr. Piotr K. Krajewski

Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, 50-368 Wroclaw, Poland

Deadline for manuscript submissions

31 August 2025



Current Issues in Molecular Biology

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 3.7 Indexed in PubMed



mdpi.com/si/196379

Current Issues in Molecular Biology Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 cimb@mdpi.com

mdpi.com/journal/cimb





Current Issues in Molecular Biology

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 3.7 Indexed in PubMed

About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Madhav Bhatia

Department of Pathology and Biomedical Science, University of Otago, Christchurch, 2 Riccarton Avenue, P.O. Box 4345, Christchurch 8140, New Zealand

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PMC, PubMed, Embase, CAPlus / SciFinder, FSTA, AGRIS, and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.8 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).

Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and reviewer names are published annually in the journal.

